Swiss National Bank Increases Position in Sotera Health (NASDAQ:SHC)

Swiss National Bank raised its holdings in shares of Sotera Health (NASDAQ:SHC – Get Rating) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 239,100 shares of the company’s stock after buying an additional 4,400 shares during the period. Swiss National Bank owned about 0.08% of Sotera Health worth $1,992,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of SHC. Boston Partners boosted its holdings in shares of Sotera Health by 243.2% in the third quarter. Boston Partners now owns 3,109,343 shares of the company’s stock valued at $20,997,000 after purchasing an additional 2,203,400 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in shares of Sotera Health by 3,594.8% in the third quarter. Cubist Systematic Strategies LLC now owns 1,378,845 shares of the company’s stock valued at $9,404,000 after purchasing an additional 1,341,526 shares during the period. Two Sigma Investments LP bought a new position in Sotera Health in the third quarter worth approximately $7,422,000. State Street Corp raised its stake in Sotera Health by 75.5% in the second quarter. State Street Corp now owns 2,518,749 shares of the company’s stock worth $49,342,000 after buying an additional 1,083,900 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Sotera Health in the third quarter worth approximately $5,764,000. Hedge funds and other institutional investors own 87.21% of the company’s stock.

Wall Street Analyst Weigh In

SHC has been the subject of a number of recent research reports. Barclays reduced their price objective on shares of Sotera Health from $21.00 to $20.00 in a research note on Thursday, May 4th. Royal Bank of Canada boosted their price objective on shares of Sotera Health from $8.00 to $19.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 1st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Sotera Health has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Sotera Health Stock Performance

Shares of SHC stock opened at $14.12 on Friday. The business’s fifty day simple moving average is $16.33 and its 200-day simple moving average is $14.01. The company has a market cap of $3.99 billion, a PE ratio of -15.18 and a beta of 2.08. The company has a current ratio of 1.54, a quick ratio of 1.46 and a debt-to-equity ratio of 6.32. Sotera Health has a 12-month low of $5.78 and a 12-month high of $24.90.

Sotera Health (NASDAQ:SHC – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The business had revenue of $251.59 million for the quarter, compared to the consensus estimate of $247.66 million. Sotera Health had a positive return on equity of 46.84% and a negative net margin of 26.47%. Analysts expect that Sotera Health will post 0.75 earnings per share for the current fiscal year.

Sotera Health Profile

(Get Rating)

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.